Article info

Download PDFPDF

Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy

Authors

  • Prashant Ramesh Tembhare Hematopathology Laboratory, Tata Memorial Centre, Navi Mumbai, Maharashtra, IndiaHomi Bhabha National Institute, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Harshini Sriram Hematopathology Laboratory, Tata Memorial Centre, Navi Mumbai, Maharashtra, IndiaHomi Bhabha National Institute, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Twinkle Khanka Hematopathology Laboratory, Tata Memorial Centre, Navi Mumbai, Maharashtra, IndiaHomi Bhabha National Institute, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Gaurav Chatterjee Hematopathology Laboratory, Tata Memorial Centre, Navi Mumbai, Maharashtra, IndiaHomi Bhabha National Institute, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Devasis Panda Hematopathology Laboratory, Tata Memorial Centre, Navi Mumbai, Maharashtra, IndiaHomi Bhabha National Institute, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Sitaram Ghogale Hematopathology Laboratory, Tata Memorial Centre, Navi Mumbai, Maharashtra, IndiaHomi Bhabha National Institute, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Yajamanam Badrinath Hematopathology Laboratory, Tata Memorial Centre, Navi Mumbai, Maharashtra, IndiaHomi Bhabha National Institute, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Nilesh Deshpande Hematopathology Laboratory, Tata Memorial Centre, Navi Mumbai, Maharashtra, IndiaHomi Bhabha National Institute, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Nikhil V Patkar Hematopathology Laboratory, Tata Memorial Centre, Navi Mumbai, Maharashtra, IndiaHomi Bhabha National Institute, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Gaurav Narula Homi Bhabha National Institute, Mumbai, Maharashtra, IndiaDepartment of Pediatric Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Bhausaheb Bagal Homi Bhabha National Institute, Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Hasmukh Jain Homi Bhabha National Institute, Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Manju Sengar Homi Bhabha National Institute, Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Navin Khattry Homi Bhabha National Institute, Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Shripad Banavali Homi Bhabha National Institute, Mumbai, Maharashtra, IndiaDepartment of Pediatric Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Sumeet Gujral Hematopathology Laboratory, Tata Memorial Centre, Navi Mumbai, Maharashtra, IndiaHomi Bhabha National Institute, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  • Papagudi G Subramanian Hematopathology Laboratory, Tata Memorial Centre, Navi Mumbai, Maharashtra, IndiaHomi Bhabha National Institute, Mumbai, Maharashtra, India PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Prashant Ramesh Tembhare; docprt{at}gmail.com
View Full Text

Citation

Tembhare PR, Sriram H, Khanka T, et al
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy

Publication history

  • Accepted April 20, 2020
  • First published May 20, 2020.
Online issue publication 
May 20, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.